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I. Introduction

(i) Sedolisin Family of Enzymes and Their Structures
Proteolytic enzymes (peptidases, proteinases or proteases) catalyze the cleavage of
peptide bonds and form one of the largest and very important groups of enzymes.
Sedolisins, also known as serine-carboxyl peptidases, are members of the MEROPS family
of peptidades, S53 proteolytic enzymes. Their fold resembles that of subtilisin; however,
they are considerably larger than subtilisin, with the mature catalytic domains containing
approximately 375 amino acids.1 Other common properties among sedolisins include the
lack of inhibition by pepstatin, stabilization by a Ca2+, and presence of conserved acidic
residues required for the activity.
Structural comparison for two members of the family of serine-carboxyl peptidases,
sedolisin (PSCP)2, 3 and kumamolisin (KSCP)4 based on published crystal structures shows
that the three-dimensional fold of sedolisin (PSCP) contains a 7-stranded, all-parallel β sheet
(strands s2-s3-s1-s4-s5-s6-s7b). This β sheet is flanked on the both sides by several helices
(Fig. 1A,B).1 In addition, the fold of sedolisin contains several additional shorter strands and
helices, with three pairs of strands (s8-s9, s6`b-s6``a, and s6``b-s7a) forming β hairpins on
the surface of the proteins. Helix h2 is absent in kumamolisin, whereas an additional short
strand (s1a), absent in sedolisin, is observed in kumamolisin.4 The core of kumamolisin
consists of a highly twisted β sheet, flanked by five helices on both sides, composed of eight
parallel β strands arranged in the sequential order s2, s3, s1, s4, s5, s6, s7, and s11 (Fig. 1C
).4 The differences in the structures of sedolisin and kumamolisin are mainly limited to the
surface areas, while the cores of both enzymes are rather similar.1 Both sedolisin and
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kumamolisin have a Ca+2 binding site that seems to be in similar positions in all structures of
the family reported so far. The structural role of this site in sedolisin seems to tie the long
loop containing residues 328–342 to a short loop, 343–348, and both of them to opposite
strands around residue 353; experiments about this site suggest the importance of the
integrity of the Ca+2 binding site for the activity of the enzyme.1
Serine-carboxyl peptidases have maximum activity at low pH. One possible reason
for this behavior is that a key Asp residue (e.g., Asp170 in sedolisin and Asp164 in
kumamolisin) would need to be protonated in order to serve its function;1 as a consequence,
this event is favored at higher concentration of H+. The active site of serine-carboxyl
peptidases contains a unique catalytic triad Ser-Glu-Asp (SED in the single letter code) that
differs from classical serine proteases. Details of catalytic mechanisms, substrate
specificities and the role of the active-site residues are still poorly understood for this
sedolisin family of enzymes.
One of the important members of the sedolisin family is tripeptidyl peptidase-1
(TPP1), which represents the only known mammalian member of the sedolisin family. As
discussed before, this group of enzymes is characterized by a subtilisin-like fold, the SerGlu-Asp catalytic triad and maximum enzymatic activity at low pH. A mutation in the
CLN2 gene that encodes for this protein (TPP1) may cause a fatal neurodegenerative disease
of childhood known as late infantile neuronal ceroid lipofuscinosis. The gene product is
initially synthesized as an inactive proenzyme that is autocatalytically converted to an active
form.5
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Fig.1. (A) Stereo tracing of the Cα backbone of sedolisin (PSCP). The key active site
residues are shown in stick representation. α-helices, -strands and loops are in purple,
gold and green, respectively. Calcium cation is shown as a black sphere. Wlodawer et
al. 2003 (PDB ID:1ke2). (B) Schematic secondary structure diagram of sedolisin
showing the names of α helices and strands. Single and double primes represent the
structural elements present only in sedolisin but not in subtilisin. Wlodawer et al.
2003. (C) Stereo ribbon plot of kumamolisin (KSCP) with the covalently bond AcIAF-CHO inhibitor shown as a yellow stick model (PDB ID:1gtj). The residues from
the catalytic and the calcium cation are shown in orange stick models and orange
sphere, respectively. Comellas-Bigler et al. 2002
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The crystal structures for the proform of TPP1 were recently solved at 1.85 Å and
2.35 Å resolution, respectively.6,

7

X-ray crystallographic analysis reveals a globular

structure with a subtilisin-like fold, a S475-E272-D276 catalytic triad and an octahedrally
coordinated Ca2+ binding site which are all characteristic features of the S53 sedolisin
family of peptidases.7 Chemical modification studies of TPP1 have revealed that S475 is the
active-site nucleophile.5
TPP1 has a primary tripeptidyl exopeptidase activity with a pH optimum of ~5.0 and
catalyzes the sequential release of tripeptides from the unsubstituted N-termini of
substrates.6 An example of this tripeptidyl exopeptidase activity is when TPP1 releases GlyPro-X triplets from synthetic collagen-like polymers, suggesting that it may be involved in
part of the pathway leading to the degradation of the bone matrix proteins or bone
resorption.8 The acidic pH optimum suggests that TPP1 has a lysosomal localization, and
experimental data show that this enzyme is inhibited by reagents that modify serine and
histine residues.8 The mechanism for activity of TPP1 to release tripeptides is still poorly
understood, but recent studies suggest that a kind of ‘molecular ruler’ in the enzyme, which
ensures the mechanism that removes tripeptides and not longer or shorter fragments, with
the positively charged N-terminal amino group being the essential determinant for this
activity.9 Another example of this molecular ruler mechanism is observed in the role of Glu331 and Glu-305 in substrate binding of tripeptidyl-peptidase II.9
TPP1 is the eukaryotic homolog of the prokaryotic kumamolisin. Because of these
similarities, the study of kumamolisin (or kumamolisin-As, which has over 90% sequence
identity with kumamolisin) could provide more clues to better understand the chemical basis
of the neuronal disease. In this thesis, two reported X-ray crystal structures of TPP1 are

Valenzuela

7

examined to better understand the acylation reaction. Molecular dynamics simulations are
performed to understand the dynamic nature of the key amino-acids in the active site, the
solvent and the peptide substrate.

(ii) Neuronal Lipoid Fuscinosis
The neuronal ceroid lipofuscinoses (NCLs) are a group of related hereditary
neurodegenerative disorders in which there is an accumulation of autofluorescent lysosomelike bodies in the neurons and other cells and that occur at a frequency of between 2 and 4 in
100000 live births.10, 11 Absence of TPP1 results in lysosomal storage with an accompanying
axonal degeneration throughout the central nervous system (CNS), which leads to this
progressive neurodegeneration and early death.12
Diagnosis is based on problems with vision, behavioral changes and seizures. All
childhood forms are eventually fatal. There is no effective treatment for NCL, and
progression is reflected by a decline in mental abilities, increasingly severe and untreatable
seizures, blindness and loss of motor skills.13 This lysosomal storage disease of childhood
typically presents between the ages of 2 and 4 years with the onset of seizures.6 However,
enzyme and gene therapy are promising approaches that will be discussed in this senior
thesis. Both of them could rescue TPP1 activity and prevent or slow disease progression.
Risk Factors, Pathology and Clinical Factors
According to a 2006 pediatric neurology online article by Celia Chang,14 the
neuronal ceroid lipofuscinosis, also known as Baten Disease, are the most common of the
neurogenetic storage diseases with a prevalence of 1 in 12.500 in some populations. Seizure,
dementia, visual loss and cerebral atrophy are some examples of the progressive symptoms.
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Batten made the first clinicopathologic correlation in 1903 and pointed out the differences
from Tay–Sachs disease. Pathophysiology studies show that patients with CLN2 mutated
gene are deficient in TPP1 enzyme, which is in charge of removing tripeptides from the Nterminal of polypeptides. More than fifty-two mutations have been reported in all 13 exons
of the CLN2 gene. A recent study have reported the currently known pathogenic mutations
on the TPP1 structure (Fig. 2).7

Fig.2. Pathogenic TPP1 missense
mutations mapped onto the TPP1
structure as labeled spheres.
Mutations
compromising
the
catalytic activity, conformational
destabilization
and
unclear
structural
consequences
are
represented as red, blue and gray
colored spheres, respectively. Pal et
al. 2008

Patients with NCL have short life expectancy; how short depends on the type of
NCL. In the US approximately 25,000 families are affected with a form of NCL. In the
particular type CLN2, the worldwide prevalence is 0.6–0.7 per million inhabitants, with an
incidence of 0.46 per 1.000.000 live births.14
Clinical differences are important to properly identify the type of NCL. As
previously mentioned, the deficiency in TPP1, which is the focus of this thesis, is related
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with the CLN2 or Jansky–Bielschowsky type or late infantile neuronal ceroid lipofuscinosis
(LINCL). The other types includes the CLN1 or Santavuori–Haltia type or infantile NCL,
the CLN3 or Spielmeyer–Sjogren type or adult NCL, the CLN4 or Kufs disease or adult
NCL, the CLNS or Finnish Variant late infantile NCL, the CLN6 or Variant late
infantile/early juvenile NCL, the CLN7 or Turkish variant late infantile NCL, the CLN8 or
Turkish variant late infantile NCL and Northern epilepsy.14
Laboratories studies are useful to diagnose the disease. For the CNL2 type, the
levels of TPP1 in leukocytes, cultured fibroblasts, dried blood spots, and saliva can be
measured and then compared to normal levels. For instance, fibroblast TPP1 activity is
approximately 17.000 micromoles of amino acids produced per hour per mg. of protein,
while the activity of TPP1 in LICNL is less than 4% of normal. In addition, other
biochemical abnormalities can be detected such as the ATP synthase complex subunit C
accumulation in lysosomes of patients. Other applicable types of tests are DNA testing and
electron microscopy ultrastructural findings.14
Current Treatment/Therapies
Currently there is no treatment of demonstrated efficacy for the late infantile
neuronal ceroid lipofuscinosis (LINCL), but some advances are being made in some fields.
Proof-of-principle for a viral-mediated gene therapy has been established in a mouse model
of LINCL, with a significant improvement in disease phenotype achieved with the use of
adeno-associated virus (AAV) vectors expressing TPP1. The results emphasize the
importance of early intervention for enhanced therapeutic benefit, which may provide
guidance in designing novel treatment strategies for LINCL patients.6,

12

Recently AAV

vectors has been used as part of the therapy for affected children. Although the clinical
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benefits are still under study, this trial was not matched, randomized, or blinded and lacked a
placebo control group. Assessment of the primary outcome variable suggests a slowing of
progression of LINCL in the treated children.15 Enzyme replacement therapy is another
approach that was already successful with other lysosomal storage diseases and that is
currently being investigated in LINCL.6 Purified recombinant human TPP1 that contains the
mannose 6-phosphate lysosomal targeting modification can be taken up by LINCL
fibroblasts were it degrades storage material, and the protein has been introduced into the
cerebrospinal fluid of the LINCL mouse model via intraventricular injection. This infusion
of recombinant human TPP1 through an intraventricular cannula led to enzyme distribution
in several regions of the brain of treated mice, resulting in significant uptake into the brain
and some correction of neuropathology.6, 16

II. Computational Studies of Tripeptidyl Peptidase-1 (TPP1)

(i) Methods
The X-ray crystal structures of the enzyme studied, TPP1, were obtained from the
Protein Data Bank (PDB ID: 3ee6 and 3edy). Both structures were superimposed using
MOE 2007 software to construct a model that contains the five amino acid peptide of the
linker fragment (Gly-Pro-Hsp-Phe-Phe). Hydrogen atoms and water molecules were added
using MOE. The key amino acids surrounding the five amino acid peptide to a distance of
4.5 Å were selected with the rest of the system fixed (in order to focus only on the desired
area for study). Energy minimization with a gradient of 0.00001 was performed on the
model, and CHARMM22 was used as the force field. Molecular dynamics simulations were
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performed for 4000 steps (4ns) with 0.002ps time step and the temperature of 300 K. The
root-mean-square deviation (RMSD) compares the position of atoms before and after the
dynamics simulations. Once the 4-ns dynamic simulation ended, the RMSD values of the
key amino acids and the substrate were plotted and compared.

(ii) Results
The TPP1 model analyzed by MOE reveals all the features discussed above. The
analysis of the elements of secondary structure for this enzyme reveals the number of βstrands and α-helices already described in the introduction (Fig.3A). The catalytic triad
(Fig.3B) and the five amino acid link peptide (Fig.3C) reveal a series of H-bonding
interactions between Ash276-Glu272 (two hydrogen bonds), Ser475-Hsp3, and Phe4-Pro2
before the dynamic simulations (Fig. 3C).
After 4-ns molecular dynamic simulations, the average conformations of the
residues from the catalytic triad, Asp360 and the substrate have new hydrogen-bonding
interactions between Ash360-Hsp3, Ser475-Gly1, and Ash276-Glu272. Ash represents the
protonated Asp residues. The color of the residues in Fig. 3D shows how dynamic (based
on RMSD) these residues are, with the red color indicating the most dynamic residues and
the blue color the relatively less dynamic during the simulations.
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Fig.3. (A) 3-D Structure of the two chains of proenzyme TPP1 (PDB ID 3ee6) with α-helices
and β-sheets colored in red and yellow, respectively. (B) The catalytic triad of the TPP1
(Ser475-Asp276-Glu272) and the also relevant Asp360, all them are important for the acid–
base mechanism of acylation. (C) Structure of the catalytic triad and Ash360 with the 5-amino
acid peptide (orange, ball and stick). Non-covalent H-bonding interactions are displayed. (D)
Averaged structures and interactions after molecular dynamic simulations. Color represents
differences in RMSD, being the red the most and the blue the less dynamic. Hydrogen-bonding
interactions are observed between Ash360-Hsp3, Ser475-Gly1, and Ash276-Glu272.
Protonated Asp is labeled as Ash.
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FIG.4. RMSD for the 5-amino acid substrate and surrounding residues (4.5Å). The
peptide substrate (Gly1-Pro2-Hsp3-Phe4-Phe5) and relevant residues (Glu272, Ash360,
Ser475) are labeled. Asp276 (not labeled) shows a lower RMSD of about zero.

The final outcome of the script using MOE shows a plot of RMSD against residue
number to show the variation in position comparing system before and after the 4-ns
dynamic simulation. The residues from the five-amino acid substrate show the highest
RMSD values (Fig.4).

(iii) Discussion
MOE is very useful software that can help predict possible conformations and
dynamics of residues through computer simulations. The 4-ns molecular dynamics
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simulations provided information about the motion and position of the residues of interest as
well as the change of the structure from the initial one after the dynamics simulation. The
highest RMSD values correspond to the peptide substrate, suggesting that it may undergo
significant changes in the conformations because the initial conformation is presumably
unstable. Among the catalytic triad, Glu272 shows the highest RMSD value, followed by
Ser475 and then Ash360. Three hydrogen-bond interactions involving Ash360- Hsp3,
Ser475-Gly1, and Ash276-Glu272 were found to be stable after 4-ns simulations. No
apparent stabilizing interactions are observed between Phe4/Phe5 and the key surrounding
residues, and as a consequence, the last two residues from the substrate are more likely to be
dynamic and have high RMSD values. The initial hydrogen bonding interactions in the
constructed model (before running the 4-ns dynamics simulation) are between Ash276Glu272 (two hydrogen bonds), Ser475-Hsp3, and Phe4-Pro2.

III. Computational Studies of Kumamolisin-As (Kum-As)

Kumamolisin-As (Kum-As) is an acid collagenase with a subtilisin-like fold. Its
active site contains a unique catalytic triad, Ser278-Glu78-Asp82 (as in kumamolisin), and a
putative transition-state stabilizing residue, Asp164.17 Kum-As is a member of the sedosilin
family identified by Tsuruoka et al. culture filtrate of a thermoacidophilic soil bacterium,
Alicyclobacillus sendaiensis strain NTAP-1.18, 19 Kum-As is encoded as a 57-kDa precursor
protein consisting of an N-terminal prodomain and a catalytic domain.17 The side chain
residues from the catalytic triad (Ser278-Glu78-Asp82) are connected by hydrogen-bond
interactions, which are extended out to two additional residues, Glu32 and Trp129.4, 20 It is
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important to note that kumamolisin is 93% identical with kumamolisin-As in its primary
structure.17 Kum-As is the first example of a collagenase from the sedolisin family
(MEROPS53).20 Collagen (~30% of the total weight of animal proteins) is an insoluble

Fig.5. Suggested mechanism for the formation of the tetrahedral adduct
(hemiacetal) from the aldehyde complex in the active site of kumamolisinAs by the nucleophilic attack of Ser278. Proton subject of this study are
colored in red. Guo et al. 2006
structural protein predominant constituent of skin, cartilage and tendons; collagen provides
the structure and strength in nearly all extracellular matrix of organs by being present in the
connective tissue as insoluble fibers.21
As a sedolisin family member, the kumamolisin-As have a Ser-Glu-Asp catalytic
triad (Ser278-Glu78-Asp82) and the presence of an aspartic acid residue (Asp164), a residue
in charge of the creation of the oxyanion hole in classical serine proteases. An early study
suggested that kumamolisin-As stabilizes the tetrahedral intermediates and adducts primarily
through a general acid–base mechanism with Asn164 acting as a general acid catalyst to
protonate the tetrahedral intermediate and assist in the nucleophilic attack by Ser278. The
Glu78 next to Ser278 is likely to act as the general base to accept the proton from Ser278
(Fig.5).22 2D free energy map studies demonstrate that the proton transfer from Ser278 to
Glu78 (the general base catalyst) is synchronous with the nucleophilic attack, whereas the
proton transfer from Asp164 (the general acid catalyst) to the inhibitor is not.23 This Asp
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residue act as a general acid catalyst to stabilize the tetrahedral intermediate, leading to the
rate acceleration for the enzyme-catalyzed reaction in contrast with the serine protease
mechanism of electrostatic interactions of the oxyanion-hole used for stabilizing the
tetrahedral intermediate during catalysis.23
In this thesis, the acylation reaction catalyzed by kumamolisin-As of the 5-peptide
substrate is analyzed using quantum mechanical/molecular mechanical (QM/MM) molecular
dynamics (MD) and free energy (potential of mean force) simulations.

(i) Methods
QM/MM molecular dynamics (MD) and free-energy (potential of mean force)
simulations were performed using Chemistry and Harvard Molecular Mechanics
(CHARMM) program with the semi-empirical density-functional method (SCC-DFTB). The
initial coordinates for the X-ray crystal structures (pro-kumamolisin and kumamolisin-As)
were obtained from the Protein Data Bank (ID: 1t1e and 1sio, respectively). The structures
were superimposed, and the five amino acid peptide of the linker fragment from 1t1e was
used to generate the substrate for kumamolisin-As leading to wild-type kumamolisin-Assubstrate complex. A model of the D164N–substrate complex was also built by the
superposition of the apo structure of D164N (Protein Data Bank ID: 1zvj) and the structure
of pro-kumamolisin (ID:1t1e) in which the linker peptide GPHFF of 1t1e was used to
generate the substrate. The models were optimized by using MOE software.
Protons were manually added to some ionizable residues to mimic the structures
determined a low pH environment. The method of stochastic boundary, optimized by
adopted basis Newton–Rhaphson (ABNR), was applied for the QM/MM simulations,
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separating the system into the reservoir zone and the reaction zone. The latter was further
separated into the reaction region and the buffer region. For the MM region, the allhydrogen potential function (PARAM22) was used, to separate both the MM and the QM
region, the link atom approach was employed. A modified TIP3P water model was used as
solvent, and explicit water spheres covering the area of study were applied to solvate the
systems.

To determine the change of free energy for the acylation reaction of the

kumamolisin wild type and single mutant, the umbrella sampling method and the Weighted
Histogram Analysis Method (WHAM) were applied to this study.

(ii) Results and Discussion
Kum-As X-ray crystal structure shows the entire characteristics discussed above
(Fig. 6B). All these features were analyzed using the useful tools in MOE to display
residues. The average active site structure provides a better idea of the role of the catalytic
triad, especially the nucleophile Ser278 (Fig. 6A)
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FIG.6. (A) Average active site structures for the atoms involved in nucleophilic attack in
the aldehyde and hemiacetal complexes, Guo, H et al. 2006. (B) Pro-Kumamolisin
secondary structure (PDB ID 1T1E)

The reaction coordinate [ = r(C-N) – r(C-Oγ)] is the difference between the bond
distance of the scissile peptide bond [r(C-N)] and the [r(Oγ(Ser278)-C)] distance of the
nucleophilic attack during the acylation reaction. The free-energy plots in Fig. 7 show that
the free-energy barrier of the acylation reaction is considerably lower for the wild-type
Kum-As compared to that in the D164N mutant, which is consistent with experimental
observations that the D164A mutant of kumamolisin (which is very similar to kumamolisinAs) did not show any measurable proteolytic activity.4
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Fig.7. Free energy profiles of the acylation reaction for the wild-type kumamolisin-As
and D164N single mutant as a function of the reaction coordinate [ξ= r(C-N) - r(C-Oγ]
obtained from the QM/MM free energy (potential of mean force) simulations.

Asp164 seems to facilitate the acylation reaction, as it is demonstrated by the
results of the simulations that the free-energy barrier increases significantly as a result of
D164→N mutation. The proposed acid–base mechanism for stabilization of the reaction
intermediates depends on the role of Asp164 as a general acid catalyst. This property is
lost when D164 is mutated to Asn.

Conclusion
Understanding the structure and function of TPP1 is crucial for developing possible
therapies and treatments against people with late neuronal ceroid lipofuscinosis that is a
consequence of the mutation in the CLN2 gene that encodes for TPP1. New research
advances are on their way, especially after the presence of new and more adequate X-ray
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crystal structure data. The studies of TPP1, as well as the enzymes in the same family (e.g.,
Kum-As), could potentially increase the understanding of TPP1. QM/MM molecular
dynamics simulation reveals the importance of D360 in TPP1 (and D164 in Kum-As) and its
role as the acid–base catalyst for the acylation step.
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